Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Clinical trial NCT05284617 · COMPLETED

Trial details

NCT number

NCT05284617

Sponsor

Rivus Pharmaceuticals, Inc.

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2022-10-30

Primary completion

2024-05-24

Enrollment

67

View on ClinicalTrials.gov